Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer
04 January 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the appointment of Richard L. Beckman , M.D. to the position of Chief Medical Officer.
03 January 2017
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment of Fragile X Syndrome (FXS).
14 December 2016
Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, for intramural preclinical and clinical research.
Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index
14 December 2016
Ñlearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NBI). The annual re-ranking of the NBI will become effective at market open on Monday, December 19, 2016 .
Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock
09 December 2016
Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discount.
Clearside Biomedical, Inc. Announces Proposed Offering of Common Stock
07 December 2016
Clearside Biomedical , Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the offering will be sold by Clearside. In addition, Clearside expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discount.
Epic Sciences Validates Single CTC Sequencing, Identifies Clonal Heterogeneity in Metastatic Cancer
16 November 2016
Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC). In addition to profiling genome wide copy number variation (CNV) from single cells, the authors also validated the ability to characterize the extent of genomic instability within individual CTCs.
15 November 2016
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data showing that the combination of its CNS-selective GABAA modulator ganaxolone and diazepam administered intravenously (IV) produced a synergistic effect in blocking pilocarpine-induced seizures in a benzodiazepine refractory model of status epilepticus (SE).
15 November 2016
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced the enrollment of the first patient in a Phase 1/2 clinical trial (the “HULK” trial) of Zuprata™, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, for the treatment of diabetic macular edema (“DME”).
Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
10 November 2016
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the third quarter ended September 30, 2016. In addition, the Company provided a pipeline update as well as a review of upcoming milestones. As of September 30, 2016, Syndax had $115.6 million in cash, cash equivalents and short-term investments.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024
Microbial burden assessment of solid pharmaceutical products
22 April 2024
Seasonal variation of microbial contamination in pharmaceutical cleanrooms
22 April 2024